| Followers | 24 |
| Posts | 1345 |
| Boards Moderated | 0 |
| Alias Born | 01/24/2004 |
Sunday, June 28, 2020 4:04:47 PM
I hope I'm not duplicating any efforts, but I sent a message to Adam Write, the organizer of the Go Fund Me page, asking if there is something that could be set up so that stock shares can be donated/transferred. Maybe he'll get back to me, or is already responding to one of your messages.
I feel that perhaps leronlimab is today as what penicillin was in 1942.
Although study results hopefully demonstrate efficacy and safety, I am reminded of the fact that Goldman and other large investment banks are heavily invested in Moderna, Gilead, and other biotech competitors. So, while I'm optimistic, I wouldn't be surprised if politics gives rise to the FDA not granting immediate approval. The good side of that is that it would more time to continue loading up on shares, and could even result in a big pull back where shares can be picked up much more cheaply.
Chuckles, I do have experience with how clinical studies are performed - I've been involved in three - and they go like this: Talk as many people into the study as possible, promise them medical treatment if anything goes wrong, hope nobody dies, make sure anyone who has serious side effects drop out so they don't have to be reported, and forget about any patients who were harmed.
I feel that perhaps leronlimab is today as what penicillin was in 1942.
Although study results hopefully demonstrate efficacy and safety, I am reminded of the fact that Goldman and other large investment banks are heavily invested in Moderna, Gilead, and other biotech competitors. So, while I'm optimistic, I wouldn't be surprised if politics gives rise to the FDA not granting immediate approval. The good side of that is that it would more time to continue loading up on shares, and could even result in a big pull back where shares can be picked up much more cheaply.
Chuckles, I do have experience with how clinical studies are performed - I've been involved in three - and they go like this: Talk as many people into the study as possible, promise them medical treatment if anything goes wrong, hope nobody dies, make sure anyone who has serious side effects drop out so they don't have to be reported, and forget about any patients who were harmed.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
